{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:17:59Z","timestamp":1788556679133,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.phrs.2022.106620","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T10:52:06Z","timestamp":1678531926000},"page":"106620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["IUPHAR \u2013 invited review - Ibogaine \u2013 A legacy within the current renaissance of psychedelic therapy"],"prefix":"10.1016","volume":"190","author":[{"given":"Deborah C.","family":"Mash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106620_bib1","first-page":"71","article-title":"Pharmacodynamics and therapeutic applications of iboga and ibogaine","volume":"6","author":"Goutarel","year":"1993","journal-title":"Psychedelic Monogr. Essays"},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02860623","article-title":"Tabernanthe iboga: an African narcotic plant of social importance","volume":"23","author":"Pope","year":"1969","journal-title":"Econ. Bot."},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib3","first-page":"251","article-title":"Religion of Eboga or the Bwiti of the Fangs","volume":"42","author":"Barabe","year":"1982","journal-title":"Med Trop. (Mars)"},{"key":"10.1016\/j.phrs.2022.106620_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0099-9598(01)56017-4","article-title":"\"Returning to the path\": the use of iboga[ine] in an equatorial African ritual context and the binding of time, space, and social relationships","volume":"56","author":"Fernandez","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib5","first-page":"16","article-title":"Ibogaine in the treatment of chemical dependence disorders: clinical perspectives","volume":"5","author":"Lotsof","year":"1995","journal-title":"MAPS"},{"key":"10.1016\/j.phrs.2022.106620_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0099-9598(01)56018-6","article-title":"A contemporary history of ibogaine in the United States and Europe","volume":"56","author":"Alper","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jep.2007.08.034","article-title":"The ibogaine medical subculture","volume":"115","author":"Alper","year":"2008","journal-title":"J. Ethnopharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106620_bib8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/17425255.2021.1944099","article-title":"Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse","volume":"17","author":"Luz","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib9","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(95)00273-9","article-title":"Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin","volume":"57","author":"Mash","year":"1995","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF02805969","article-title":"Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine","volume":"127","author":"Staley","year":"1996","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.phrs.2022.106620_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0099-9598(01)56009-5","article-title":"Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine","volume":"56","author":"Baumann","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"issue":"40","key":"10.1016\/j.phrs.2022.106620_bib12","doi-asserted-by":"crossref","first-page":"29441","DOI":"10.1074\/jbc.M704456200","article-title":"Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter","volume":"282","author":"Jacobs","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2022.106620_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0361-9230(99)00053-2","article-title":"The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes","volume":"48","author":"Wells","year":"1999","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.phrs.2022.106620_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0099-9598(01)56012-5","article-title":"Ibogaine in the treatment of heroin withdrawal","volume":"56","author":"Mash","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"key":"10.1016\/j.phrs.2022.106620_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuropharm.2015.08.032","article-title":"Noribogaine is a G-protein biased kappa-opioid receptor agonist","volume":"99","author":"Maillet","year":"2015","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02245936","article-title":"Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity","volume":"118","author":"Sweetnam","year":"1995","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0006-8993(92)90661-R","article-title":"Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies","volume":"571","author":"Deecher","year":"1992","journal-title":"Brain Res"},{"issue":"22","key":"10.1016\/j.phrs.2022.106620_bib18","doi-asserted-by":"crossref","first-page":"18524","DOI":"10.1074\/jbc.M112.343681","article-title":"The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters","volume":"287","author":"Bulling","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"7754","key":"10.1016\/j.phrs.2022.106620_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-019-1135-1","article-title":"Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport","volume":"569","author":"Coleman","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3940(95)11608-Y","article-title":"Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex","volume":"192","author":"Mash","year":"1995","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0028-3908(96)84107-4","article-title":"Ibogaine block of the NMDA receptor: in vitro and in vivo studies","volume":"35","author":"Chen","year":"1996","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/BF02245000","article-title":"The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex","volume":"114","author":"Popik","year":"1994","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106620_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0006-8993(95)00123-8","article-title":"Radioligand-binding study of noribogaine, a likely metabolite of ibogaine","volume":"675","author":"Pearl","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2022.106620_bib24","series-title":"The Alkaloids","first-page":"197","article-title":"Pharmacology of Ibogaine and Ibogaine-Related Alkaloids","author":"Popik","year":"1999"},{"issue":"9","key":"10.1016\/j.phrs.2022.106620_bib25","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.biocel.2010.05.011","article-title":"Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states","volume":"42","author":"Arias","year":"2010","journal-title":"Int J. Biochem Cell Biol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.51.1.1","article-title":"Ibogaine: a potent noncompetitive blocker of ganglionic\/neuronal nicotinic receptors","volume":"51","author":"Badio","year":"1997","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-3565(24)37928-5","article-title":"Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine","volume":"288","author":"Fryer","year":"1999","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.phrs.2022.106620_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.2000.tb05211.x","article-title":"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action","volume":"914","author":"Glick","year":"2000","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106620_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(02)01284-0","article-title":"Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration","volume":"438","author":"Glick","year":"2002","journal-title":"Eur. J. Pharm."},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106620_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2004.03.062","article-title":"Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration","volume":"492","author":"Pace","year":"2004","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib31","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0014-2999(95)00247-I","article-title":"Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity","volume":"279","author":"Bowen","year":"1995","journal-title":"Eur. J. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib32","doi-asserted-by":"crossref","first-page":"PL57","DOI":"10.1016\/0024-3205(95)00301-L","article-title":"Ibogaine possesses a selective affinity for sigma 2 receptors","volume":"57","author":"Mach","year":"1995","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.phrs.2022.106620_bib33","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1177\/0269881116641331","article-title":"Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents","volume":"30","author":"Mash","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0893-133X(99)00003-2","article-title":"Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain","volume":"21","author":"Zubaran","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1527-3458.2000.tb00149.x","article-title":"Ibogaine and noribogaine: comparing parent compound to metabolite","volume":"6","author":"Zubaran","year":"2000","journal-title":"CNS Drug Rev."},{"issue":"6","key":"10.1016\/j.phrs.2022.106620_bib36","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jcph.471","article-title":"Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers","volume":"55","author":"Glue","year":"2015","journal-title":"J. Clin. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2022.106620_bib37","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/cpdd.254","article-title":"Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients","volume":"5","author":"Glue","year":"2016","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"529","key":"10.1016\/j.phrs.2022.106620_bib38","article-title":"Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes","volume":"9","author":"Mash","year":"2018","journal-title":"Front Pharm."},{"issue":"23","key":"10.1016\/j.phrs.2022.106620_bib39","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1021\/jm980156y","article-title":"Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes","volume":"41","author":"Efange","year":"1998","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106620_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179069518800508","article-title":"Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics","volume":"12","author":"Olson","year":"2018","journal-title":"J. Exp. Neurosci."},{"issue":"7842","key":"10.1016\/j.phrs.2022.106620_bib41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106620_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/26331055211033847","article-title":"Engineering safer psychedelics for treating addiction","volume":"16","author":"Peters","year":"2021","journal-title":"Neurosci. Insights"},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.31887\/DCNS.2017.19.3\/rspanagel","article-title":"Animal models of addiction","volume":"19","author":"Spanagel","year":"2017","journal-title":"Dialog-. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF02246099","article-title":"Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats","volume":"117","author":"Dworkin","year":"1995","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0014-2999(91)90474-5","article-title":"Effects and aftereffects of ibogaine on morphine self-administration in rats","volume":"195","author":"Glick","year":"1991","journal-title":"Eur. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106620_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0006-8993(94)90948-2","article-title":"Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum","volume":"657","author":"Glick","year":"1994","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0166-4328(94)90080-9","article-title":"The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine","volume":"65","author":"Cappendijk","year":"1994","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.phrs.2022.106620_bib48","first-page":"64","article-title":"Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats","volume":"294","author":"Dzoljic","year":"1988","journal-title":"Arch. Int Pharm. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2022.106620_bib49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0028-3908(92)90089-8","article-title":"Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor","volume":"31","author":"Glick","year":"1992","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.phrs.2022.106620_bib50","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0278-5846(03)00109-X","article-title":"Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors","volume":"27","author":"Leal","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0278-5846(01)00268-8","article-title":"Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine","volume":"26","author":"Parker","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"8\u20139","key":"10.1016\/j.phrs.2022.106620_bib52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1472-8206.1992.tb00127.x","article-title":"Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice","volume":"6","author":"Frances","year":"1992","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.phrs.2022.106620_bib53","first-page":"477","article-title":"Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine dependent rat","volume":"105","author":"Sharpe","year":"1990","journal-title":"NIDA Res Monogr."},{"key":"10.1016\/j.phrs.2022.106620_bib54","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","article-title":"Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures","volume":"914","author":"Mash","year":"2000","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0091-3057(94)90092-2","article-title":"Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies","volume":"49","author":"Broderick","year":"1994","journal-title":"Pharm. Biochem Behav."},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106620_bib56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0014-2999(93)90212-Z","article-title":"Inhibitory effects of ibogaine on cocaine self-administration in rats","volume":"241","author":"Cappendijk","year":"1993","journal-title":"Eur. J. Pharm."},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106620_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0014-2999(97)01231-4","article-title":"Time-dependent interactions between iboga agents and cocaine","author":"Maisonneuve","year":"1997","journal-title":"Eur. J. Pharm. 336("},{"issue":"15","key":"10.1016\/j.phrs.2022.106620_bib58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0024-3205(92)90344-O","article-title":"Ibogaine antagonizes cocaine-induced locomotor stimulation in mice","volume":"50","author":"Sershen","year":"1992","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib59","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0091-3057(95)00152-M","article-title":"Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats","volume":"52","author":"Rezvani","year":"1995","journal-title":"Pharm. Biochem Behav."},{"key":"10.1016\/j.phrs.2022.106620_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.739012","article-title":"Ibogaine blocks cue- and drug-induced reinstatement of conditioned place preference to ethanol in male mice","volume":"12","author":"Henriques","year":"2021","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1523\/JNEUROSCI.3959-04.2005","article-title":"Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption","volume":"25","author":"He","year":"2005","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib62","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1369-1600.2010.00251.x","article-title":"Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration","volume":"15","author":"Carnicella","year":"2010","journal-title":"Addict. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106620_bib63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0269881115584461","article-title":"Noribogaine reduces nicotine self-administration in rats","volume":"29","author":"Chang","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106620_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.71","article-title":"Ibogaine and addiction in the animal model, a systematic review and meta-analysis","volume":"6","author":"Belgers","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"6","key":"10.1016\/j.phrs.2022.106620_bib65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jat\/19.6.427","article-title":"Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry","volume":"19","author":"Hearn","year":"1995","journal-title":"J. Anal. Toxicol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106620_bib66","doi-asserted-by":"crossref","first-page":"PL119","DOI":"10.1016\/0024-3205(95)02322-4","article-title":"Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration","volume":"58","author":"Hough","year":"1996","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib67","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0306-4522(01)00333-5","article-title":"Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice","volume":"106","author":"Skoubis","year":"2001","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib68","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1037\/1064-1297.3.4.344","article-title":"Ibogaine attenuates morphine-induced conditioned place preference","volume":"3","author":"Parker","year":"1995","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0091-3057(97)00454-1","article-title":"The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus","volume":"59","author":"Helsley","year":"1998","journal-title":"Pharm. Biochem Behav."},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0091-3057(97)00452-8","article-title":"Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys","volume":"59","author":"Jones","year":"1998","journal-title":"Pharm. Biochem Behav."},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0031-6997(25)06842-5","article-title":"100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug","volume":"47","author":"Popik","year":"1995","journal-title":"Pharm. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib72","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/acsptsci.0c00164","article-title":"Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat","volume":"4","author":"Gonz\u00e1lez","year":"2021","journal-title":"ACS Pharm. Transl. Sci."},{"key":"10.1016\/j.phrs.2022.106620_bib73","first-page":"309","article-title":"Disposition of [3H]ibogaine in the rat","volume":"141","author":"Jeffcoat","year":"1994","journal-title":"NIDA Res Monogr."},{"key":"10.1016\/j.phrs.2022.106620_bib74","unstructured":"D.C. Mash, W.L. Hearn, J.P. Pablo, Pharmacokinetics of ibogaine and its primary metabolite noribogaine, University of Miami NIDA Contract, 1996."},{"key":"10.1016\/j.phrs.2022.106620_bib75","series-title":"A comparative study on the toxicity of ibogaine and serotonin","author":"Dhahir","year":"1971"},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib76","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0091-3057(96)00383-8","article-title":"Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism","volume":"57","author":"Pearl","year":"1997","journal-title":"Pharm. Biochem Behav."},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib77","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000136294","article-title":"Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids","volume":"7","author":"Zetler","year":"1972","journal-title":"Pharmacology"},{"issue":"11","key":"10.1016\/j.phrs.2022.106620_bib78","first-page":"2194","article-title":"Cumulation of Tabernanthe Iboga alkaloid and its metabolite in organs of mice","volume":"6","author":"Kubilien\u0117","year":"2012","journal-title":"J. Med. Plants Res."},{"key":"10.1016\/j.phrs.2022.106620_bib79","first-page":"1591","article-title":"Investigation into pharmacokinetic properties of active alkaloid ibogaine and its metabolite noribogaine","volume":"74","author":"Kubiliene","year":"2017","journal-title":"Acta Pol. Pharm."},{"issue":"8","key":"10.1016\/j.phrs.2022.106620_bib80","first-page":"764","article-title":"Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine","volume":"26","author":"Obach","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2022.106620_bib81","first-page":"287","article-title":"Gender differences in the metabolism of ibogaine to noribogaine in rats","volume":"180","author":"Baumann","year":"1999","journal-title":"NIDA Res. Monogr."},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib82","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0376-8716(99)00113-1","article-title":"Comparative neurobiological effects of ibogaine and MK-801 in rats","volume":"59","author":"Baumann","year":"2000","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1358\/mf.2000.22.2.796066","article-title":"Pharmacokinetic characterization of the indole alkaloid ibogaine in rats","volume":"22","author":"Hough","year":"2000","journal-title":"Methods Find. Exp. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib84","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1556\/2054.01.2016.001","article-title":"The antiaddictive effects of ibogaine: a systematic literature review of human studies","volume":"1","author":"Dos Santos","year":"2017","journal-title":"J. Psychedelic Stud."},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib85","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02791072.2018.1487607","article-title":"Analysis of persisting effects associated with positive outcomes following ibogaine detoxification","volume":"50","author":"Davis","year":"2018","journal-title":"J. Psychoact. Drugs"},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib86","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine","volume":"8","author":"Alper","year":"1999","journal-title":"Am. J. Addict."},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib87","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0740-5472(94)90049-3","article-title":"A preliminary investigation of ibogaine: case reports and recommendations for further study","volume":"11","author":"Sheppard","year":"1994","journal-title":"J. Subst. Abus. Treat."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib88","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study","volume":"44","author":"Noller","year":"2018","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib89","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","article-title":"Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes","volume":"44","author":"Brown","year":"2018","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1556\/2054.2018.004","article-title":"A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders","volume":"2","author":"Camlin","year":"2018","journal-title":"J. Psychedelic Stud."},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib91","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1556\/2054.01.2017.009","article-title":"Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning","volume":"1","author":"Davis","year":"2017","journal-title":"J. Psychedelic Stud."},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib92","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","article-title":"Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine","volume":"50","author":"Malcolm","year":"2018","journal-title":"J. Psychoact. Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1521-0391.1998.tb00472.x","article-title":"Observations on treatment with ibogaine","volume":"7","author":"Luciano","year":"1998","journal-title":"Am. J. Addict."},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib94","article-title":"Neurologic, electroencephalographic and general medical observations in subjects administered ibogaine","volume":"9","author":"Luciano","year":"2000","journal-title":"MAPS"},{"key":"10.1016\/j.phrs.2022.106620_bib95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1749-6632.2000.tb06687.x","article-title":"Ibogaine in acute opioid withdrawal. An open label case series","volume":"909","author":"Alper","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.phrs.2022.106620_bib96","unstructured":"E. Bastiaans, Life after Ibogaine: An exploratory study of the long-term effects of ibogaine treatment on drug addicts, Vrije Universiteit Amsterdam, 2004."},{"issue":"9","key":"10.1016\/j.phrs.2022.106620_bib97","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2022.106620_bib98","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pharmthera.2018.06.011","article-title":"Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases","volume":"191","author":"Schverer","year":"2018","journal-title":"Pharm. Ther."},{"issue":"7","key":"10.1016\/j.phrs.2022.106620_bib99","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2022.106620_bib100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0166-2236(96)80018-X","article-title":"Metaplasticity: the plasticity of synaptic plasticity","volume":"19","author":"Abraham","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2022.106620_bib101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coph.2020.09.005","article-title":"Glutamate receptors and metaplasticity in addiction","volume":"56","author":"Chiamulera","year":"2021","journal-title":"Curr. Opin. Pharm."},{"issue":"12","key":"10.1016\/j.phrs.2022.106620_bib102","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","article-title":"Psychedelic psychiatry\u2019s brave new world","volume":"181","author":"Nutt","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2022.106620_bib104","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fpsyt.2019.00311","article-title":"Addiction, anhedonia, and comorbid mood disorder. A narrative review","volume":"10","author":"Destoop","year":"2019","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1369-1600.2012.00447.x","article-title":"Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk","volume":"19","author":"Koenig","year":"2014","journal-title":"Addict. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib106","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3390\/molecules20022208","article-title":"The anti-addiction drug ibogaine and the heart: a delicate relation","volume":"20","author":"Koenig","year":"2015","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.phrs.2022.106620_bib107","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/add.15448","article-title":"Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study","volume":"117","author":"Knuijver","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2022.106620_bib108","first-page":"1","article-title":"Reply to Knuijver et al. on the 'Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study'","author":"Luz","year":"2022","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.phrs.2022.106620_bib109","first-page":"491","article-title":"Importance of QT\/RR hysteresis correction in studies of drug-induced QTc interval changes","volume":"45","author":"Malik","year":"2018","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.phrs.2022.106620_bib110","unstructured":"National Library of Medicine, A Study of Oral Ibogaine in Opioid Withdrawal ClinicalTrials.gov Identifier NCT05029401. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05029401. 2022 (Accessed 14 November 2022)."},{"key":"10.1016\/j.phrs.2022.106620_bib111","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/bs.pbr.2018.08.005","article-title":"Ibogaine as a treatment for substance misuse: potential benefits and practical dangers","volume":"242","author":"Corkery","year":"2018","journal-title":"Prog. Brain Res"},{"issue":"2","key":"10.1016\/j.phrs.2022.106620_bib112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1590\/0101-60830000000231","article-title":"An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers","volume":"47","author":"Bouso","year":"2020","journal-title":"Arch. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.phrs.2022.106620_bib113","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.phrs.2022.106620_bib114","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00005344-200111000-00010","article-title":"Drug block of I(kr): model systems and relevance to human arrhythmias","volume":"38","author":"Yang","year":"2001","journal-title":"J. Cardiovasc Pharm."},{"issue":"7","key":"10.1016\/j.phrs.2022.106620_bib115","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-111-7-549","article-title":"Amiodarone and Torsade de Pointes","volume":"111","author":"Lazzara","year":"1989","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.phrs.2022.106620_bib116","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8369.1","article-title":"Neurobiology of opioid dependence in creating addiction vulnerability","volume":"5","author":"Evans","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.phrs.2022.106620_bib117","unstructured":"National Library of Medicine, Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification ClinicalTrials.gov Identifier NCT04003948. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04003948 (Accessed August 31, 2022)."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:43:51Z","timestamp":1760913831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822005667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":117,"alternative-id":["S1043661822005667"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106620","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IUPHAR \u2013 invited review - Ibogaine \u2013 A legacy within the current renaissance of psychedelic therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106620"}}